Bevacizumab improves success rate of augmented trabeculectomy for neovascular glaucoma in young diabetic patients

The addition of bevacizumab (Avastin) to trabeculectomy improves the success rate of IOP control, particularly in young diabetic patients with neovascular glaucoma (NVG), according to a study published online, ahead of print, by Eye.

Related Content:

ArticlesGlaucoma

Expanding the definition of AMD

Combined MIGS and cataract surgery option offers positive results

Study evaluates periodic aflibercept injections in NPDR treatment